Press

  • BioEurope Spring 2016

    Posted on February 29, 2016 by Annie De Groot
    We’re off to Stockholm for BIO-Europe Spring (BES2016), which will take place 4–6 April in Stockholm, Sweden. We will be joining international leaders from biotech, pharma and finance to identify and enter new strategic relationships. Sign up to meet us now through the partnering system or via email
    Read more
  • EpiVax at Bio Asia 2016

    Posted on February 29, 2016 by Annie De Groot
    Lucky us! the 13th International Bio Asia Conference is scheduled for March 15-16, 2016 at the Grand Hyatt, Tokyo in Roppongi. It might be a bit early for cherry blossoms, but hope springs eternal! We will be arriving a bit early and staying a bit late. Please let us know if you would like us to meet with you ...
    Read more
  • We rush to conquer Zika, but . . . how?

    Posted on February 14, 2016 by Annie De Groot
    As a Valentine’s day gift to women at risk of Zika everywhere, we’re providing access to our initial analysis of Zika and our opinion on Zika vaccine design.  If you just want access to the slides, here they are: http://bit.ly/Zika_Slides_EpiVax_2016 What’s the key point of this post? We think that it’s won’t be so easy to make an effective Zika vaccine. Rushing ...
    Read more
  • Zika envelope is a 'stealth protein'

    Posted on February 6, 2016 by Annie De Groot
    The fact that we (EpiVax folk) haven’t said much about Zika probably has people scratching their heads. Well … here you have it We say: proceed with caution. Why? Zika is a Flavivirus, and that means it’s an RNA virus. That means lots of rapid evolution (the virus changes rapidly over time) and that has proven to be ...
    Read more
  • Zika envelope is a ‘stealth protein’

    Posted on February 6, 2016 by Annie De Groot
    The fact that we (EpiVax folk) haven’t said much about Zika probably has people scratching their heads. Well … here you have it We say: proceed with caution. Why? Zika is a Flavivirus, and that means it’s an RNA virus. That means lots of rapid evolution (the virus changes rapidly over time) and that has proven to be ...
    Read more
  • Step into the 21st Century, Novartis!

    Posted on February 1, 2016 by Annie De Groot
    (This post has been corrected, thanks Sebastian!) I love “Google Alerts”. They let me know when someone has just published an article citing one of our articles, and link me to new, exciting work that has just been made available on the web. Last week, my google alert linked me to a new paper by Sebastian Spindeldreher’s ...
    Read more
  • New publication in IQT Quarterly

    Posted on January 24, 2016 by Annie De Groot
    Our latest mini-publication on ‘vaccines on demand’ can be found here: IQT Quarterly Winter 2016 – EpiVax
    Read more
  • And the winner of a new Hoverboard is . . .

    Posted on January 24, 2016 by Annie De Groot
    Sancha Salgueiro! Congratulations to Sancha and the team at ExpreS2ion Biotechnologies! https://www.linkedin.com/in/sanchasalgueiro
    Read more
  • Bacteria adopt Immune Camouflage

    Posted on January 23, 2016 by Annie De Groot
    Graduate student Lu He, working with EpiVax CEO De Groot and collaborator Chris Bailey Kellog, recently reported that bacteria ‘copy and paste’ sequences from the human genome to escape immune response. She calls this escape mechanism “bacterial immune camouflage“. She used the JanusMatrix tool to develop a new measure of immune escape,  the Janus Immunogenicity Score ...
    Read more
  • The Immune System Achilles’ Heel

    Posted on January 21, 2016 by Annie De Groot
    An academic version of this blog post, that explains why epitope redundancy provides resiliency (to bacteria) and weakness (to immune defense) can be found here.  . . . So a guy named Elledge has discovered a way to test your blood for the viruses that you’ve been exposed to. Sounds as if it will soon be available ...
    Read more
  • The Immune System Achilles' Heel

    Posted on January 21, 2016 by Annie De Groot
    An academic version of this blog post, that explains why epitope redundancy provides resiliency (to bacteria) and weakness (to immune defense) can be found here.  . . . So a guy named Elledge has discovered a way to test your blood for the viruses that you’ve been exposed to. Sounds as if it will soon be available ...
    Read more
  • EpiVax Spins Out Aceno Biotherapeutics at JP Morgan/Biotech Showcase 2016

    Posted on January 11, 2016 by Steven Vessella
    PROVIDENCE, R.I., Jan. 11, 2016 /PRNewswire/ — EpiVax, Inc. (EpiVax) today announced the company’s participation in a new venture, Aceno Biotherapeutics, a BioSuperior company. Co-founder Anne S. De Groot MD will be presenting the vision for the new venture in San Francisco at the Hilton Union Square in San Francisco, at 4 PM (Davidson). Aceno ...
    Read more
  • A Computational Pipeline for Personalized Cancer Vaccines

    Posted on December 7, 2015 by Annie De Groot
    A short time ago, we received an email that contained an individual patient’s cancer genome. The patient had appealed to his doctor to make a personalized cancer vaccine, and his doctor emailed us, to ask if we could help out. Our answer? Yes we can! A bigger question might be – how will the patient get permission to ...
    Read more
  • Raimondo Works to Spark Innovation Economy

    Posted on November 23, 2015 by Steven Vessella
    Rhode Island offers companies access to research and development to help them grow PROVIDENCE, R.I. – Governor Gina M. Raimondo, along with Secretary of Commerce Stefan Pryor, today launched three new innovation-focused incentive programs aimed at jumpstarting Rhode Island’s economy. Applications for the Innovation Vouchers, Industry Cluster Grants and Innovation Network Matching Grants are now available ...
    Read more
  • EpiVax: Cliff Grimm (MD) and Bill Martin (CIO)

    EpiVax Accelerating Innovation, Growth

    Posted on November 17, 2015 by Steven Vessella
    Seventeen years ago EpiVax Inc. spun out of a laboratory at Brown University – a high-risk but high-reward company whose founders had made an innovative discovery. Today the self-funded, Providence-headquartered company is at the forefront of vaccine research. Its computational tools enable developers to engineer and design safe, effective and protective therapeutic proteins and vaccines, and ...
    Read more

Join our newsletter

We strive to provide our clients, collaborators and everyday immunology enthusiasts with valuable content.  Written by our CEO/CSO Dr. Anne Dr Groot, you can expect up to date vaccine development efforts, upcoming events and so much more from our offices here in Providence, RI.

Click Here